The Indian government unveiled on 27 July detailed guidelines for twin schemes aimed at driving investments in bulk drug production in the country, against a backdrop of rising drug nationalism and a need to reduce raw materials dependency on China after COVID-19 disruption. The INR69.4bn ($928m) scheme, providing incentives for 41 key starting materials (KSMs), drug intermediates (DIs) and active pharmaceutical ingredients (APIs), and a separate program on setting up of three bulk drug plants entailing a INR30bn investment, were first proposed in March.
P D Vaghela, secretary, Department of Pharmaceuticals (DoP), said India planed to attract foreign direct investment (FDI) through these schemes....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?